Progesterone Receptor antibody (PR) content of breast cancer tissue is an important parameter in the prediction of prognosis and response to endocrine therapy. PR  is directed against the human progesterone receptor molecule. A prokaryotic recombinant protein, corresponding to the N-terminal region of the A-form of human progesterone receptor, was used as the immunogen. Antibody characterization studies demonstrated that PR  reacts with both A- and B- forms of human progesterone receptor in Western Blotting procedures.
|Download OUS Datasheet|
IVD is NOT for Sale in the United States but may be available in certain countries outside of the United States, please contact your local distributor for more information.
1. Qiu J, et al. Effect of delayed formalin fixation on estrogen and progesterone receptors in breast cancer: a study of three different clones. Am J Clin Pathol. 2010 Nov; 134(5):813-9.
2. Arihito K, et al. Comparison of evaluations for hormone receptors in breast carcinomas using two manual and three automated immunohistochemical assays. Am J Clin Pathol. 2007 Mar; 127(3):356-65.
3. Press M, et al. Comparison of different antibodies for detection of progesterone receptor in breast cancer steroids. Steroids. 2002 Aug; 67(9):799-813.
4. Mote P, et al. Detection of progesterone receptor forms A and B by immunohistochemical analysis. J Clin Pathol. 2001 Aug; 54(8):624-30.
5. Bevitt D, et al. New monoclonal antibodies to oestrogen and progesterone receptors effective for paraffin section immunohistochemistry. J Pathol. 1997 Oct; 183(3):228-32.
6. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
7. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory workers from occupationally Acquired Infections; Approved guideline-Third Edition CLSI document M29-A3 Wayne, PA 2005.